“Burns fat” is too imprecise to be a complete scientific explanation. It can refer to lower fat mass over months, increased oxidation of fatty acids, greater energy expenditure, or simply a person's interpretation of weight loss. Those are related ideas, but they require different measurements.
Receptor-structure research investigates how retatrutide interacts with GLP-1, GIP and glucagon receptors. This helps explain why researchers study a compound with several receptor activities. It does not measure how many additional calories a particular person expends, establish the cause of their weight change, or demonstrate that appetite is irrelevant.
A 2026 exploratory analysis of two phase 2 trials examined lipid and metabolite changes associated with retatrutide. The authors described clusters related to fatty-acid oxidation and insulin resistance. These were biochemical measurements and statistical analyses, not a direct demonstration that every participant's increased energy expenditure caused their observed weight reduction.
Mediation analysis is especially easy to overread. It models how variables may relate within the available data and assumptions. It is not the same as separately randomizing appetite and energy expenditure, nor does it isolate every mechanism. A plausible pathway can remain scientifically interesting without being quantified well enough to predict an individual's response.
The distinction matters when someone considers escalating treatment despite already noticing an appetite effect. A mechanistic explanation does not provide a personal dose target. More receptor exposure cannot be assumed to yield an acceptable additional benefit for that person, and an online report about eating freely while losing weight does not establish energy balance or product identity.
The useful question is therefore specific: which outcome was measured, in which population, and with what comparator? Human body-weight studies, metabolic sampling and laboratory receptor experiments can complement one another without becoming interchangeable. This article does not recommend investigational use or a regimen. It explains why “only appetite suppression” and “automatic fat burning” are both inadequate summaries of a developing evidence base, and why the next clinical decision cannot be read directly from a pathway diagram.